Next Article in Journal
Antioxidant and Antimutagenic Activities of Different Fractions from the Leaves of Rhododendron arboreum Sm. and Their GC-MS Profiling
Previous Article in Journal
Antinociceptive Effects of Cardamonin in Mice: Possible Involvement of TRPV1, Glutamate, and Opioid Receptors
Article Menu
Issue 9 (September) cover image

Export Article

Open AccessReview
Molecules 2018, 23(9), 2238; https://doi.org/10.3390/molecules23092238

Use of Polyamidoamine Dendrimers in Brain Diseases

1
College of Medicine, Central Michigan University, Mt. Pleasant, MI 48859, USA
2
Field Neurosciences Institute Laboratory for Restorative Neurology, Central Michigan University, Mt. Pleasant, MI 48859, USA
3
Program in Neuroscience, Central Michigan University, Mt. Pleasant, MI 48859, USA
4
Department of Chemistry & Biochemistry, Central Michigan University, Mt. Pleasant, MI 48859, USA
5
Department of Psychology, Central Michigan University, Mt. Pleasant, MI 48859, USA
6
Field Neurosciences Institute, St. Mary’s of Michigan, Saginaw, MI 48604, USA
These authors contributed equally to this work.
*
Authors to whom correspondence should be addressed.
Received: 30 July 2018 / Revised: 24 August 2018 / Accepted: 28 August 2018 / Published: 3 September 2018
(This article belongs to the Section Medicinal Chemistry)
Full-Text   |   PDF [545 KB, uploaded 3 September 2018]   |  

Abstract

Polyamidoamine (PAMAM) dendrimers are one of the smallest and most precise nanomolecules available today, which have promising applications for the treatment of brain diseases. Each aspect of the dendrimer (core, size or generation, size of cavities, and surface functional groups) can be precisely modulated to yield a variety of nanocarriers for delivery of drugs and genes to brain cells in vitro or in vivo. Two of the most important criteria to consider when using PAMAM dendrimers for neuroscience applications is their safety profile and their potential to be prepared in a reproducible manner. Based on these criteria, features of PAMAM dendrimers are described to help the neuroscience researcher to judiciously choose the right type of dendrimer and the appropriate method for loading the drug to form a safe and effective delivery system to the brain. View Full-Text
Keywords: PAMAM dendrimers; nanoparticles; blood-brain barrier; DNA delivery; drug delivery; neurodegenerative diseases PAMAM dendrimers; nanoparticles; blood-brain barrier; DNA delivery; drug delivery; neurodegenerative diseases
Figures

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Florendo, M.; Figacz, A.; Srinageshwar, B.; Sharma, A.; Swanson, D.; Dunbar, G.L.; Rossignol, J. Use of Polyamidoamine Dendrimers in Brain Diseases. Molecules 2018, 23, 2238.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Molecules EISSN 1420-3049 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top